Ribosomal aminoacyl-tRNA binding site (A-site)

The ribosomal aminoacyl-tRNA binding site, commonly referred to as the A-site, is a fundamental component of the ribosome's decoding center responsible for the elongation phase of protein translation. It is the primary location where the incoming aminoacyl-tRNA, complexed with elongation factors, matches its anticodon with the mRNA codon to ensure accurate protein synthesis (Alberts et al., Molecular Biology of the Cell, 2002). In bacteria, the A-site is located on the 30S small ribosomal subunit and is composed largely of highly conserved sequences of the 16S ribosomal RNA (rRNA). This site is a major therapeutic target for various classes of antibiotics, most notably aminoglycosides and tetracyclines (StatPearls, 2023). Aminoglycosides bind to the A-site and induce a conformational change that causes the ribosome to misread the genetic code, leading to the production of toxic, non-functional proteins. Tetracyclines, conversely, sterically hinder the binding of aminoacyl-tRNA to the A-site, effectively halting protein production (Wilson, Nature Reviews Microbiology, 2014). While these drugs are designed to be selective for bacterial ribosomes, their potential to interact with human mitochondrial ribosomes—which share structural similarities with bacterial ribosomes—can lead to clinical safety concerns such as ototoxicity and nephrotoxicity.

Other names

Ribosomal A-siteAminoacyl siteAcceptor site30S A-site40S A-siteDecoding center

Drugs targeting the A-site typically inhibit protein synthesis by either physically blocking the binding of aminoacyl-tRNA or by inducing conformational changes in the decoding center that lead to the incorporation of incorrect amino acids (mistranslation).